Denmark Said No to a DKK 2.5m CAR-T in January and Yes Once Kite Tied the Price to Response
Denmark turned a January no on Tecartus into a yes by tying price to response, and renewed burosumab on a lower price.
NeuroPulse
DealPulse Signal
The Beats
Analysis
The Briefs
Denmark Said No to a DKK 2.5m CAR-T in January and Yes Once Kite Tied the Price to Response
Out of 452 Brain Regions, an Overlooked Hypothalamic Nucleus Set the Volume on Stress in Mice
Australia Set a Price Lilly Refused, So Lilly Built a Channel Around the PBS
Merck and Daiichi Pulled an ADC Filing as GSK Paid $110 Million for a KRAS Payload
ICER Says AstraZeneca’s $10,950 Baxfendy Is Worth $1,400 to $2,500 a Year
